Get started
Author

Fabian Mueller

Observed name: Mueller, Fabian
OpenAlex ID: A5067009586
CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients
2023 · Fabian Mueller, Jule Taubmann, et al. · Blood · 18
Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients
2023 · Veit L. Buecklein, Kai Rejeski, et al. · Blood · 13
Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria
2023 · Anna Ruckdeschel, Koemm Sabrina, et al. · Blood · 10
Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
2025 · Maike Breidenbach, Peter Bader, et al. · Journal of Hematology & Oncology · 7
PDF
Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
2024 · Johannes Waldschmidt, David Fandrei, et al. · Blood · 6
PDF
CAR-T Cell Therapy in Patients with Refractory Systemic Autoimmune Diseases Exhibits Less Inflammation, Toxicities and Different Cellular Dynamics Compared to Patients with B Cell Lymphoma
2023 · Fabian Mueller, Nora Rebecca Schwingen, et al. · Blood · 6
Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease
2024 · Fabian Mueller, Melanie Hagen, et al. · Blood · 5
PDF
Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies
2024 · Fabian Mueller, Krish Patel, et al. · Blood · 4
PDF
Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
2024 · Nico Gagelmann, Friedrich Stölzel, et al. · Blood · 2
PDF
Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma - a Single-Center Experience
2024 · Nora Rebecca Schwingen, Fabian Mueller, et al. · Blood · 2
Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL
2024 · Giulia Magno, Kai Rejeski, et al. · Blood · 2
PDF
Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL
2022 · Viktoria Blumenberg, Galina Busch, et al. · Blood · 2
Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy
2022 · Hannah Reimann, Anita Natalie Kremer, et al. · Blood · 2
CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients
2022 · Fabian Mueller, Simon Voelkl, et al. · Blood · 1
Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
2025 · Breidenbach, Maike, Bader, Peter, et al. · Zurich Open Repository and Archive (University of Zurich)
CD19 CAR-T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia (AIHA) With Concurrent Immune Thrombocytopenia (ITP) and Antiphospholipid Antibody Syndrome (APLAS)
2025 · Isabel K. Korte, Soraya Kharboutli, et al. · SSRN Electronic Journal
P-023 Efficacy and Safety of CAR T-cell Therapy for Plasma Cell Leukemia
2024 · Nico Gagelmann, Danai Dima, et al. · Clinical Lymphoma Myeloma & Leukemia
Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults
2023 · Maike Breidenbach, Peter Bader, et al. · Blood
PDF
Nex-T TM Cluster of Differentiation 19 (CD19) Chimeric Antigen Receptor (CAR) T-Cell Therapy BMS-986353 (CC-97540): Comparative Analysis of Baseline Patient Data from Trials in Systemic Lupus Erythematosus (SLE) and Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Related to Manufacturability and Potential Safety
2023 · Fabian Mueller, Julie Rytlewski, et al. · Blood
PDF
Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response
2022 · Franziska Gsottberger, Christina Meier, et al. · Blood
Works count: 21
Citation count: 80
H-index: 6
I10-index: 3
Year
Topic
Type